577 related articles for article (PubMed ID: 24563539)
21. Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth.
Garapaty-Rao S; Nasveschuk C; Gagnon A; Chan EY; Sandy P; Busby J; Balasubramanian S; Campbell R; Zhao F; Bergeron L; Audia JE; Albrecht BK; Harmange JC; Cummings R; Trojer P
Chem Biol; 2013 Nov; 20(11):1329-39. PubMed ID: 24183969
[TBL] [Abstract][Full Text] [Related]
22. Conformationally constrained potent inhibitors for enhancer of zeste homolog 2 (EZH2).
Xu X; Chen J; Wang G; Zhang X; Li Q; Zhou X; Guo F; Li M
Bioorg Med Chem Lett; 2024 Jan; 97():129558. PubMed ID: 37956762
[TBL] [Abstract][Full Text] [Related]
23. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation.
Qi W; Chan H; Teng L; Li L; Chuai S; Zhang R; Zeng J; Li M; Fan H; Lin Y; Gu J; Ardayfio O; Zhang JH; Yan X; Fang J; Mi Y; Zhang M; Zhou T; Feng G; Chen Z; Li G; Yang T; Zhao K; Liu X; Yu Z; Lu CX; Atadja P; Li E
Proc Natl Acad Sci U S A; 2012 Dec; 109(52):21360-5. PubMed ID: 23236167
[TBL] [Abstract][Full Text] [Related]
24. An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1.
Konze KD; Ma A; Li F; Barsyte-Lovejoy D; Parton T; Macnevin CJ; Liu F; Gao C; Huang XP; Kuznetsova E; Rougie M; Jiang A; Pattenden SG; Norris JL; James LI; Roth BL; Brown PJ; Frye SV; Arrowsmith CH; Hahn KM; Wang GG; Vedadi M; Jin J
ACS Chem Biol; 2013; 8(6):1324-34. PubMed ID: 23614352
[TBL] [Abstract][Full Text] [Related]
25. ABCB1 and ABCG2 restrict the brain penetration of a panel of novel EZH2-Inhibitors.
Zhang P; de Gooijer MC; Buil LC; Beijnen JH; Li G; van Tellingen O
Int J Cancer; 2015 Oct; 137(8):2007-18. PubMed ID: 25868794
[TBL] [Abstract][Full Text] [Related]
26. EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma.
Kusakabe Y; Chiba T; Oshima M; Koide S; Rizq O; Aoyama K; Ao J; Kaneko T; Kanzaki H; Kanayama K; Maeda T; Saito T; Nakagawa R; Kobayashi K; Kiyono S; Nakamura M; Ogasawara S; Suzuki E; Nakamoto S; Yasui S; Mikata R; Muroyama R; Kanda T; Maruyama H; Kato J; Mimura N; Ma A; Jin J; Zen Y; Otsuka M; Kaneda A; Iwama A; Kato N
Sci Rep; 2021 Nov; 11(1):21396. PubMed ID: 34725436
[TBL] [Abstract][Full Text] [Related]
27. An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.
Qi W; Zhao K; Gu J; Huang Y; Wang Y; Zhang H; Zhang M; Zhang J; Yu Z; Li L; Teng L; Chuai S; Zhang C; Zhao M; Chan H; Chen Z; Fang D; Fei Q; Feng L; Feng L; Gao Y; Ge H; Ge X; Li G; Lingel A; Lin Y; Liu Y; Luo F; Shi M; Wang L; Wang Z; Yu Y; Zeng J; Zeng C; Zhang L; Zhang Q; Zhou S; Oyang C; Atadja P; Li E
Nat Chem Biol; 2017 Apr; 13(4):381-388. PubMed ID: 28135235
[TBL] [Abstract][Full Text] [Related]
28. Elevating H3K27me3 level sensitizes colorectal cancer to oxaliplatin.
Wang Q; Chen X; Jiang Y; Liu S; Liu H; Sun X; Zhang H; Liu Z; Tao Y; Li C; Hu Y; Liu D; Ye D; Liu Y; Wang M; Zhang X
J Mol Cell Biol; 2020 Feb; 12(2):125-137. PubMed ID: 31065671
[TBL] [Abstract][Full Text] [Related]
29. Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors.
Gibaja V; Shen F; Harari J; Korn J; Ruddy D; Saenz-Vash V; Zhai H; Rejtar T; Paris CG; Yu Z; Lira M; King D; Qi W; Keen N; Hassan AQ; Chan HM
Oncogene; 2016 Feb; 35(5):558-66. PubMed ID: 25893294
[TBL] [Abstract][Full Text] [Related]
30. EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas.
Mohammad F; Weissmann S; Leblanc B; Pandey DP; Højfeldt JW; Comet I; Zheng C; Johansen JV; Rapin N; Porse BT; Tvardovskiy A; Jensen ON; Olaciregui NG; Lavarino C; Suñol M; de Torres C; Mora J; Carcaboso AM; Helin K
Nat Med; 2017 Apr; 23(4):483-492. PubMed ID: 28263309
[TBL] [Abstract][Full Text] [Related]
31. Structure of the catalytic domain of EZH2 reveals conformational plasticity in cofactor and substrate binding sites and explains oncogenic mutations.
Wu H; Zeng H; Dong A; Li F; He H; Senisterra G; Seitova A; Duan S; Brown PJ; Vedadi M; Arrowsmith CH; Schapira M
PLoS One; 2013; 8(12):e83737. PubMed ID: 24367611
[TBL] [Abstract][Full Text] [Related]
32. A687V EZH2 is a gain-of-function mutation found in lymphoma patients.
Majer CR; Jin L; Scott MP; Knutson SK; Kuntz KW; Keilhack H; Smith JJ; Moyer MP; Richon VM; Copeland RA; Wigle TJ
FEBS Lett; 2012 Sep; 586(19):3448-51. PubMed ID: 22850114
[TBL] [Abstract][Full Text] [Related]
33. PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs.
Herviou L; Kassambara A; Boireau S; Robert N; Requirand G; Müller-Tidow C; Vincent L; Seckinger A; Goldschmidt H; Cartron G; Hose D; Cavalli G; Moreaux J
Clin Epigenetics; 2018 Oct; 10(1):121. PubMed ID: 30285865
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of the deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2.
Yang J; Weisberg EL; Qi S; Ni W; Mei H; Wang Z; Meng C; Zhang S; Hou M; Qi Z; Wang A; Jiang Y; Jiang Z; Huang T; Liu Q; Magin RS; Doherty L; Wang W; Liu J; Buhrlage SJ; Liu Q; Griffin JD
Leukemia; 2022 Apr; 36(4):1048-1057. PubMed ID: 35034955
[TBL] [Abstract][Full Text] [Related]
35. EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors.
Fillmore CM; Xu C; Desai PT; Berry JM; Rowbotham SP; Lin YJ; Zhang H; Marquez VE; Hammerman PS; Wong KK; Kim CF
Nature; 2015 Apr; 520(7546):239-42. PubMed ID: 25629630
[TBL] [Abstract][Full Text] [Related]
36. EZH2 inhibitors restore epigenetically silenced CD58 expression in B-cell lymphomas.
Otsuka Y; Nishikori M; Arima H; Izumi K; Kitawaki T; Hishizawa M; Takaori-Kondo A
Mol Immunol; 2020 Mar; 119():35-45. PubMed ID: 31962268
[TBL] [Abstract][Full Text] [Related]
37. Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
Woo J; Kim HY; Byun BJ; Chae CH; Lee JY; Ryu SY; Park WK; Cho H; Choi G
Bioorg Med Chem Lett; 2014 Jun; 24(11):2486-92. PubMed ID: 24767850
[TBL] [Abstract][Full Text] [Related]
38. Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer Efficacy.
Huang Y; Zhang J; Yu Z; Zhang H; Wang Y; Lingel A; Qi W; Gu J; Zhao K; Shultz MD; Wang L; Fu X; Sun Y; Zhang Q; Jiang X; Zhang J; Zhang C; Li L; Zeng J; Feng L; Zhang C; Liu Y; Zhang M; Zhang L; Zhao M; Gao Z; Liu X; Fang D; Guo H; Mi Y; Gabriel T; Dillon MP; Atadja P; Oyang C
J Med Chem; 2017 Mar; 60(6):2215-2226. PubMed ID: 28092155
[TBL] [Abstract][Full Text] [Related]
39. EZH2: a novel target for cancer treatment.
Duan R; Du W; Guo W
J Hematol Oncol; 2020 Jul; 13(1):104. PubMed ID: 32723346
[TBL] [Abstract][Full Text] [Related]
40. SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2.
Kim KH; Kim W; Howard TP; Vazquez F; Tsherniak A; Wu JN; Wang W; Haswell JR; Walensky LD; Hahn WC; Orkin SH; Roberts CW
Nat Med; 2015 Dec; 21(12):1491-6. PubMed ID: 26552009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]